Search

Showing total 18 results

Search Constraints

Start Over You searched for: Topic t cells Remove constraint Topic: t cells Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years Publication Type Periodicals Remove constraint Publication Type: Periodicals
18 results

Search Results

1. On the approximate solution of dynamic systems derived from the HIV infection of CD[formula omitted]T cells using the LRBF-collocation scheme.

2. Event-Based Distributed Filtering Over Markovian Switching Topologies.

3. A structural methodology for modeling immune-tumor interactions including pro- and anti-tumor factors for clinical applications.

4. Modeling the cytotoxicity of Romidepsin reveals the ineffectiveness of this drug in the "shock and kill" strategy.

5. Multiple bifurcations in a mathematical model of glioma-immune interaction.

6. Risk-Sensitive Linear Control for Systems With Stochastic Parameters.

7. A new fractional analysis on the interaction of HIV with [formula omitted] T-cells.

8. Partial equilibrium approximations in apoptosis. II. The death-inducing signaling complex subsystem.

9. Stability and Hopf bifurcation of a tumor–immune system interaction model with an immune checkpoint inhibitor.

10. Analysis of HIV models with multiple target cell populations and general nonlinear rates of viral infection and cell death.

11. Revealing the role of the effector-regulatory t cell loop on autoimmune disease symptoms via nonlinear analysis.

12. An immune algorithm with power redistribution for solving economic dispatch problems.

13. Dynamics of a reaction-diffusion fractional-order model for M1 oncolytic virotherapy with CTL immune response.

14. Hopf bifurcation and chaos of tumor-Lymphatic model with two time delays.

15. Analysis of Th1/Th2 response pattern with Treg cell inhibition and stochastic effect.

16. Dynamical behaviour of HIV Infection with the influence of variable source term through Galerkin method.

17. Stability of a general adaptive immunity HIV infection model with silent infected cell-to-cell spread.

18. BiTE immuno-oncology therapy appears safe with preliminary efficacy in mCRPC: More than 25% of patients show confirmed PSA response to investigational treatment.